X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MGC018 (vobramitamab duocarmazine) is an ADC which works by targeting B7-H3, is being investigated in patients with metastatic castration-resistant prostate cancer.
Lead Product(s): Vobramitamab Duocarmazine
Therapeutic Area: Oncology Product Name: MGC018
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
Under the agreement, Incyte has obtained exclusive worldwide rights for the development and commercialization of Zynyz (retifanlimab-dlwr) in all indications, while MacroGenics retained the right to develop its pipeline assets in combination with Zynyz.
Lead Product(s): Retifanlimab-dlwr
Therapeutic Area: Oncology Product Name: Zynyz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: $900.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement March 22, 2023
Details:
Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Synaffix
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Details:
MGD019 (lorigerlimab) is a bispecific IgG4-based, Fc-bearing DART molecule that was designed to enhance blockade on PD-1 and CTLA-4 dual-expressing, tumor-infiltrating lymphocytes, while maintaining maximal PD-1 blockade on all circulating PD-1-expressing cells.
Lead Product(s): Lorigerlimab,Vobramitamab Duocarmazine
Therapeutic Area: Oncology Product Name: MGD019
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Under the terms of the agreements held in 2018, Provention has acquired all rights to Tzield (teplizumab) to be further developed as PRV-031 and licensing rights to MGD010 for development as PRV-3279.
Lead Product(s): Teplizumab
Therapeutic Area: Endocrinology Product Name: Tzield
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Provention Bio
Deal Size: $395.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2022
Details:
The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Lead Product(s): MGD024
Therapeutic Area: Oncology Product Name: MGD024
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,760.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration October 17, 2022
Details:
MGA271 (enoblituzumab) is an investigational anti-B7-H3 monoclonal antibody that incorporates an immunoglobulin G1 fragment crystallizable (Fc) domain designed to enhance Fcγ receptor-mediated antibody-dependent cellular cytotoxicity.
Lead Product(s): Enoblituzumab,Retifanlimab
Therapeutic Area: Oncology Product Name: MGA271
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads for the discovery of Antibody-drug Conjugate.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Synaffix
Deal Size: $586.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 03, 2022
Details:
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules. MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors.
Lead Product(s): Bispecific Antibody-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: $1,455.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration June 16, 2021
Details:
Under its exclusive global collaboration and license agreement with Incyte. Retifanlimab is an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte.
Lead Product(s): Retifanlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: INCMGA00012
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
